{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:44:38Z","timestamp":1775123078063,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02095-6","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:55:33Z","timestamp":1775048133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["S100A8-associated inflammatory microenvironment is related to its cell-of-origin and potentiates BRAF inhibitor resistance in papillary craniopharyngioma"],"prefix":"10.1007","volume":"26","author":[{"given":"Chuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huadong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueling","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"1","key":"2095_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ecl.2007.10.012","volume":"37","author":"N Karavitaki","year":"2008","unstructured":"Karavitaki N, Wass J. Craniopharyngiomas. Endocrinol Metab Clin North Am. 2008;37(1):173\u201393. https:\/\/doi.org\/10.1016\/j.ecl.2007.10.012.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2095_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0287-6","volume":"4","author":"A H\u00f6lsken","year":"2016","unstructured":"H\u00f6lsken A, Sill M, Merkle J, et al. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun. 2016;4:20. https:\/\/doi.org\/10.1186\/s40478-016-0287-6.","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"2095_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"D Louis","year":"2021","unstructured":"Louis D, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-oncol. 2021;23(8):1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro-oncol"},{"key":"2095_CR4","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.wneu.2022.05.115","volume":"165","author":"C Zhao","year":"2022","unstructured":"Zhao C, Zhou Z, Zhang Y, et al. Diagnosis and management of pediatric papillary craniopharyngiomas. World Neurosurg. 2022;165:e148\u201358. https:\/\/doi.org\/10.1016\/j.wneu.2022.05.115.","journal-title":"World Neurosurg"},{"key":"2095_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002774","author":"X Wang","year":"2023","unstructured":"Wang X, Zhao C, Lin J, et al. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance. Chin Med J. 2023. https:\/\/doi.org\/10.1097\/cm9.0000000000002774.","journal-title":"Chin Med J"},{"key":"2095_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.652005","volume":"8","author":"M Fasano","year":"2021","unstructured":"Fasano M, Della Corte C, Caterino M, et al. Dramatic therapeutic response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: A case report and literature review. Front Med. 2021;8:652005. https:\/\/doi.org\/10.3389\/fmed.2021.652005.","journal-title":"Front Med"},{"issue":"2","key":"2095_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"389","author":"P Brastianos","year":"2023","unstructured":"Brastianos P, Twohy E, Geyer S, et al. BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med. 2023;389(2):118\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2213329.","journal-title":"N Engl J Med"},{"key":"2095_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15","author":"PK Brastianos","year":"2021","unstructured":"Brastianos PK, Twohy E, Geyer SM, et al. Alliance A071601: phase II trial of BRAF\/MEK inhibition in newly diagnosed papillary craniopharyngiomas. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/jco.2021.39.15.","journal-title":"J Clin Oncol"},{"key":"2095_CR9","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.029447","author":"V LeBleu","year":"2018","unstructured":"LeBleu V, Kalluri R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech. 2018. https:\/\/doi.org\/10.1242\/dmm.029447.","journal-title":"Dis Model Mech"},{"issue":"132","key":"2095_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejca.2020.03.025","volume":"1","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, Lacroix L, Mezquita L, et al. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non\u2013small cell lung cancer(Oxford, England\u202f: 1990). European Journal of Cancer. 2020;1(132):211\u201323.","journal-title":"European Journal of Cancer."},{"issue":"18","key":"2095_CR11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"K Flaherty","year":"2012","unstructured":"Flaherty K, Infante J, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1210093.","journal-title":"N Engl J Med"},{"issue":"1","key":"2095_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0125-9","volume":"5","author":"H M\u00fcller","year":"2019","unstructured":"M\u00fcller H, Merchant T, Warmuth-Metz M, Martinez-Barbera J, Puget S. Craniopharyngioma. Nat Rev Dis Primers. 2019;5(1):75. https:\/\/doi.org\/10.1038\/s41572-019-0125-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2095_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"D Louis","year":"2007","unstructured":"Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97\u2013109. https:\/\/doi.org\/10.1007\/s00401-007-0243-4.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2095_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4103\/neuroindia.NI_552_16","volume":"65","author":"M Tariq","year":"2017","unstructured":"Tariq M, Din N, Ahmad Z, Memon W. Papillary craniopharyngioma: a clinicopathologic study of a rare entity from a major tertiary care center in Pakistan. Neurol India. 2017;65(3):570\u20136. https:\/\/doi.org\/10.4103\/neuroindia.NI_552_16.","journal-title":"Neurol India"},{"issue":"6","key":"2095_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41568-018-0006-7","volume":"18","author":"S Maman","year":"2018","unstructured":"Maman S, Witz I. A history of exploring cancer in context. Nat Rev Cancer. 2018;18(6):359\u201376. https:\/\/doi.org\/10.1038\/s41568-018-0006-7.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2095_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99\u2013115. https:\/\/doi.org\/10.1038\/s41573-018-0004-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2095_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582\u201398. https:\/\/doi.org\/10.1038\/nrc.2016.73.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2095_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.gendis.2021.08.008","volume":"9","author":"D Zhan","year":"2022","unstructured":"Zhan D, Yalcin F, Ma D, et al. Targeting UDP-\u03b1-d-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth. Genes Dis. 2022;9(3):717\u201330. https:\/\/doi.org\/10.1016\/j.gendis.2021.08.008.","journal-title":"Genes Dis"},{"key":"2095_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2015.11.001","volume":"97","author":"A Theocharis","year":"2016","unstructured":"Theocharis A, Skandalis S, Gialeli C, Karamanos N. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4\u201327. https:\/\/doi.org\/10.1016\/j.addr.2015.11.001.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"2095_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav E, Nowarski R, Thaiss C, Hu B, Jin C, Flavell R. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759\u201371. https:\/\/doi.org\/10.1038\/nrc3611.","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"2095_CR21","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1101\/gad.1549407","volume":"21","author":"B Ancrile","year":"2007","unstructured":"Ancrile B, Lim K, Counter C. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007;21(14):1714\u20139. https:\/\/doi.org\/10.1101\/gad.1549407.","journal-title":"Genes Dev"},{"key":"2095_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.931774","volume":"12","author":"T Avery","year":"2022","unstructured":"Avery T, K\u00f6hler N, Zeiser R, Brummer T, Ruess D. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Front Oncol. 2022;12:931774. https:\/\/doi.org\/10.3389\/fonc.2022.931774.","journal-title":"Front Oncol"},{"issue":"1","key":"2095_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01322-3","volume":"15","author":"Y Yan","year":"2022","unstructured":"Yan Y, Huang L, Liu Y, et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol. 2022;15(1):104. https:\/\/doi.org\/10.1186\/s13045-022-01322-3.","journal-title":"J Hematol Oncol"},{"key":"2095_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01298","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8\/A9 in inflammation. Front Immunol. 2018;9:1298. https:\/\/doi.org\/10.3389\/fimmu.2018.01298.","journal-title":"Front Immunol"},{"issue":"6","key":"2095_CR25","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11981","volume":"25","author":"C Zhao","year":"2023","unstructured":"Zhao C, Hu W, Luo N, Wang X, Lin D, Lin Z. Expression of S100A9 in adamantinomatous craniopharyngioma and its association with wet keratin formation. Exp Ther Med. 2023;25(6):282. https:\/\/doi.org\/10.3892\/etm.2023.11981.","journal-title":"Exp Ther Med"},{"issue":"11","key":"2095_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s13258-019-00856-0","volume":"41","author":"S Hwang","year":"2019","unstructured":"Hwang S, Ahn J, Lee M. Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors. Genes Genomics. 2019;41(11):1273\u201380. https:\/\/doi.org\/10.1007\/s13258-019-00856-0.","journal-title":"Genes Genomics"},{"key":"2095_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv310","author":"P Brastianos","year":"2016","unstructured":"Brastianos P, Shankar G, Gill C, et al. Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. 2016. https:\/\/doi.org\/10.1093\/jnci\/djv310.","journal-title":"J Natl Cancer Inst"},{"key":"2095_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00049","volume":"9","author":"S Schlaffer","year":"2018","unstructured":"Schlaffer S, Buchfelder M, Stoehr R, Buslei R, H\u00f6lsken A. Rathke\u2019s cleft cyst as origin of a pediatric papillary craniopharyngioma. Front Genet. 2018;9:49. https:\/\/doi.org\/10.3389\/fgene.2018.00049.","journal-title":"Front Genet"},{"issue":"10","key":"2095_CR29","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1172\/jci119430","volume":"99","author":"S Akita","year":"1997","unstructured":"Akita S, Readhead C, Stefaneanu L, et al. Pituitary-directed leukemia inhibitory factor transgene forms Rathke\u2019s cleft cysts and impairs adult pituitary function. A model for human pituitary Rathke\u2019s cysts. J Clin Invest. 1997;99(10):2462\u20139. https:\/\/doi.org\/10.1172\/jci119430.","journal-title":"J Clin Invest"},{"issue":"4","key":"2095_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188737","volume":"1877","author":"S Halder","year":"2022","unstructured":"Halder S, Parte S, Kshirsagar P, et al. The pleiotropic role, functions and targeted therapies of LIF\/LIFR axis in cancer: old spectacles with new insights. Biochim Biophys Acta Rev Cancer. 2022;1877(4):188737. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188737.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2095_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107754","volume":"221","author":"C Zhang","year":"2021","unstructured":"Zhang C, Liu J, Wang J, Hu W, Feng Z. The emerging role of leukemia inhibitory factor in cancer and therapy. Pharmacol Ther. 2021;221:107754. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107754.","journal-title":"Pharmacol Ther"},{"issue":"7754","key":"2095_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-019-1130-6","volume":"569","author":"Y Shi","year":"2019","unstructured":"Shi Y, Gao W, Lytle N, et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019;569(7754):131\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1130-6.","journal-title":"Nature"},{"issue":"2","key":"2095_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/bf02739822","volume":"10","author":"A Tran","year":"1999","unstructured":"Tran A, Kovacs K, Stefaneanu L, Kontogeorgos G, Scheithauer B, Melmed S. Expression of leukemia inhibitory factor in craniopharyngioma. Endocr Pathol. 1999;10(2):103\u20138. https:\/\/doi.org\/10.1007\/bf02739822.","journal-title":"Endocr Pathol"},{"issue":"1","key":"2095_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/neup.12408","volume":"38","author":"K Yoshimoto","year":"2018","unstructured":"Yoshimoto K, Hatae R, Suzuki S, et al. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas. Neuropathol off j Jpn Soc Neuropathol. 2018;38(1):3\u201310. https:\/\/doi.org\/10.1111\/neup.12408.","journal-title":"Neuropathol off j Jpn Soc Neuropathol"},{"key":"2095_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01908","volume":"8","author":"C Xia","year":"2017","unstructured":"Xia C, Braunstein Z, Toomey A, Zhong J, Rao X. S100 proteins as an important regulator of macrophage inflammation. Front Immunol. 2017;8:1908. https:\/\/doi.org\/10.3389\/fimmu.2017.01908.","journal-title":"Front Immunol"},{"issue":"2","key":"2095_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMe2305288","volume":"389","author":"J Blakeley","year":"2023","unstructured":"Blakeley J, Shannon K. Precision oncology for papillary craniopharyngioma. N Engl J Med. 2023;389(2):179\u201381. https:\/\/doi.org\/10.1056\/NEJMe2305288.","journal-title":"N Engl J Med"},{"issue":"4","key":"2095_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100530","volume":"7","author":"E Borazanci","year":"2022","unstructured":"Borazanci E, Schram A, Garralda E, et al. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. ESMO open. 2022;7(4):100530. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100530.","journal-title":"ESMO open"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02095-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:45:59Z","timestamp":1775119559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02095-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2095"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02095-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was reviewed and approved by the human subjects\u2019 institutional review boards of Sanbo Brain Hospital of Capital Medical University (SBNK-YJ-2020-014-01). Written informed consent was obtained from the families of all patients whose tumor and\/or blood samples were collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}